Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 6 of the 13 calendar months from Oct 2025 to Oct 2026: Oct 2025, Jan 2026, Feb 2026, Apr 2026, May 2026 and Sep 2026.
- Largest single sale: $6.6M (101,691 shares) of Travere Therapeutics, Inc. on Sep 17, 2026. Filing
- Last sale before this period: May 5, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Chief Executive Officer, Director | Jan 8, 2019 | Sep 17, 2026 |
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Sep 17, 2026, Travere Therapeutics, Inc.: sold 108,493 shares for $7.0M, under a disclosed plan; 108,493 shares acquired by exercising options. 1 filing: 1
- Sep 16, 2026, Travere Therapeutics, Inc.: sold 195,841 shares for $12.4M, under a disclosed plan; 195,841 shares acquired by exercising options. 1 filing: 1
- Sep 15, 2026, Travere Therapeutics, Inc.: sold 95,666 shares for $6.0M, under a disclosed plan; 95,666 shares acquired by exercising options. 1 filing: 1
- May 6, 2026, Travere Therapeutics, Inc.: sold 22,500 shares for $989K, under a disclosed plan. 1 filing: 1
- May 4, 2026, Travere Therapeutics, Inc.: 22,500 shares vested. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.